Sanofi and MannKind Corp. have entered into a worldwide exclusive licensing agreement for the development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The companies plan to launch the drug in the U.S. in 1Q15. The transaction is subject to customary closing conditions.   Sanofi will be responsible for global commercial, regulatory and development activities and MannKind will manufacture ...